May 4, 2016
OncoArendi is a partner in a €8.3 million Horizon 2020 EU grant awarded to international ‘PRECIOUS’
An international multi-disciplinary consortium of 11 partners, in which 5 leading academic institutes, 4 cutting-edge biotech companies and 2 excellent service providers will join forces to advance the treatment of cancer using an innovative immunotherapeutic nanomedicine, has received an €8.3 million Horizon 2020 grant (grant agreement No 686089). The PRECIOUS consortium will be coordinated by the awarded Prof. Dr. Carl Figdor, senior professor in Experimental Immunology and head of the Tumor Immunology Department
of the Radboud University Medical Center, the Netherlands.
Read more here Press_Release_PRECIOUS.pdf
To learn more about the project, visit the EC website
April 30, 2016
OncoArendi moves into new laboratories at the University of Warsaw
By the end of March, all departments of OncoArendi Theurapeutics have moved into modern laboratories and office space located in the incubation space of the Center for Chemical & Biological Sciences of the University of Warsaw (UW). Since April, medicinal chemistry, process and analytical chemistry and biology research groups have benefited from over 400 m2
of state of the art biological and chemical laboratories featuring modern equipment acquired for execution of research and development grants co-financed by the National Center for Research and Development using European (POIR 1.1.1) and national (STRATEGMED) funds. In addition UW provides access to specialized research core facilities providing high-quality analytical services (NMR, mass spectrometry, X-ray, LCMS etc.) and unique know how of the academic research teams.
In relation to the above transition, OncoArendi management informs that as of April 1, 2016, the company headquarters have moved to:
OncoArendi Therapeutics Sp. z o.o.
Centrum Nauk Biologiczno-Chemicznych UW
Zwirki i Wigury 101
02-089 Warsaw Poland
October 9, 2015
OncoArendi Therapeutics announces selection of its first clinical development candidate
for the treatment of asthma.
On October 9, 2015, OncoArendi Therapeutics announced that it selected OATD-01 as its clinical development candidate for the treatment of asthma. Submission of the Company's first Investigational New Drug ("IND") is expected by mid-2017.
OATD-01 is an orally active, non-steroidal small molecule which is a potent inhibitor of murine and human acidic mammalian chitinase (AMCase), one of the active chitinase enzymes. Based upon available information OATD-01 is thought to be the first chitinase inhibitor to enter development. Oral administration of OATD-01 has excellent pharmacokinetic characteristics in three species, with high bioavailability, low clearance and high volume of distribution. In addition, OATD-01 has good metabolic stability, moderate plasma protein binding and does not inhibit or activate human cytochrome P450 isozymes. The overall DMPK profile of OATD‑01 is consistent with the targeted once-a-day oral dosing in humans. OATD-01 is effective in two standard mouse models of asthma (ovalbumin and house dust mite), with anti-inflammatory activity superior to montelukast (Singulair), the only current oral asthma medicine that is used regularly. OATD-01 has low potential for off-target side effects as demonstrated by clean profile in the Diversity Profile™ (Eurofins, Cerep) consisting of 98 enzymes, ion channels and receptors, and no significant effect against the hERG channel. OATD-01 is negative in the Ames mutagenicity test.
Activities in support of IND-enabling pre-clinical testing of OATD-01 are already in progress with initiation of first in human studies expected during the second half of 2017. In parallel, OncoArendi Therapeutics is planning to carry out a supplementary profiling of OATD-01, including testing of in vivo efficacy in chronic models of asthma, translational study evaluation using human lung tissue, and biomarker experiments. OncoArendi Therapeutics AMCase inhibitors, including OATD-01, are protected by three pending patents covering three structurally different groups of compounds.
OncoArendi Therapeutics has broad interest and commitment to chitinase science with three distinct small molecule drug discovery programs directed against different chitinase family targets currently in progress. Potential therapeutic applications for compounds resulting from this R&D Chitinase Platform include treatment of numerous diseases with high unmet medical need, such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD) as well as tropical diseases and some types of cancers.
October 7, 2015
OncoArendi Therapeutics receives another 20 mln PLN financing
o optimize develop its lead compound and complete a Phase I clinical trial as a first-in-class therapy of IPF.
The National Center for Research and Development (NCBR) announced results of its evaluation of project proposals submitted to the July call within the Priority I of the Smart Development Operational Program 2014-2020, Activity 1.1. “Enterprise R/D projects”, Action 1.1.1 „Industrial research and development for enterprises”. The proposals recommended for funding included the OncoArendi project entitled “Development of a first-in-class small molecule drug candidate for treatment of idiopathic pulmonary fibrosis through chitotriosidase inhibition.” This project is a continuation of the long term strategy of OncoArendi to develop anti-inflammatory small molecule therapies based on the Chitinase Platform. OncoArendi has received approx. 20 mln PLN co-financing from European Funds for the project with a budget of 25.5 mln PLN (approx. 6.5 mln USD). This funding should allow the company to advance development of the new Chit-1 inhibitor through phase I clinical trial. The project includes efficacy studies for the second indication in COPD.
August 5, 2015
OncoArendi Therapeutics receives over 22 mln financing
to take its lead compound to Phase II clinical trials as a first-in-class therapy of asthma.
The National Center for Research and Development (NCBR) announced results of its evaluation of project proposals submitted to the May call within the Priority I of the Smart Development Operational Program 2014-2020, Activity 1.1. “Enterprise R/D projects”, Action 1.1.1 „Industrial research and development for enterprises”. Among 179 proposals submitted to this call, 34 were recommended for funding. Ranked third among all proposals was OncoArendi’s project entitled “Preclinical research and clinical trials of a first-in-class development candidate in therapy of asthma and inflammatory bowel disease.” This project is a key component of the OncoArendi strategic research area of development of anti-inflammatory small molecule therapies based on the chitinase family of targets (the so-called Chitinase Platform). OncoArendi has received over 22 mln PLN co-financing from European Funds for the project with a budget of 30 mln PLN (approx. 8 mln USD). This funding should allow the company to advance development of the new AMCase inhibitor up to Phase II clinical trials.
February 10, 2015
OncoArendi Therapeutics has entered into a global license agreement with Yale University
acquiring exclusive rights to develop and commercialize a technology entitled “Inhibitors of Acidic Mammalian Chitinase (AMCase)”. Inhibitors of AMCase have been developed based on earlier discoveries of Jack A. Elias, MD, currently Dean of Medicine and Biologic Sciences and Frank L. Day Professor of Biology at Brown University. The results of his pioneering research at Yale (Science, 2004) showed that AMCase is induced during a Th2-mediated response in a mouse model of allergic airway inflammation. The relevance of these findings to the disease was also highlighted by the exaggerated expression of AMCase in human asthma.
OncoArendi Therapeutics in a project co-financed from the European Funds under the Innovative Economy Operational Programme has progressed the earlier work to show in vivo efficacy of AMCase Inhibitors in two different animal models of human asthma. Having secured over $3M in public and private funding for continuing this work, OncoArendi Therapeutics plans to identify a development candidate within the next 6 months and progress its development to IND submission and Phase I clinical trials by early 2017. In its research and development activities OncoArendi continues to collaborate with the groups of Prof. Jack A. Elias at Brown University and of Prof. Jakub Golab at the Medical University of Warsaw.
January 19, 2015
Michał Sołowow invested in OncoArendi Therapeutics Sp. z o.o.
On January 15, 2015 Michał Sołowow invested in OncoArendi Therapeutics Sp. z o.o. via the IPOPEMA 112 FIZAN fund.
OncoArendi is a dynamically growing biotechnological company, which develops innovative anti-inflammatory and antitumor drugs with unique mechanisms of actions. Twelve million PLN obtained from Series A investors, with Michał Sołowow as leading investor, will allow the company to work on its key programmes for the next three years: potential asthma therapy and a group of new compounds stimulating the anti-tumour response of the human immune system. About 4 million Poles and 300 million people worldwide suffer from asthma with more and more children developing the disease. Currently used steroid therapies have severe side effects. At the same time every year cancer is diagnosed in more than 14 million patients and it remains the most frequent cause of death worldwide. In Poland both cancer incidents and death rate are the highest among European Union countries.
Apart from the company’s unique research programs and world leading position in the area of inhibitors of proteins called chitinases, investors were attracted to OncoArendi by its team of top medicinal chemists with many years of experience in pharmaceutical and biotechnology companies in the US, outstanding molecular biologists and successful managers with experience leading high-technology companies to IPO. Crucial for the investors was also The financial support, which the Company received from NCBR, was also important for investors, because it significantly lowers the risk of long term investment in scientific research.
OncoArendi is the first biotech investment for Michał Sołowow. This sector still developing in Poland. Financing research aimed at developing innovative drugs is very risky, but if successful, the potential return on investment may be great. Acquisitions of New drug candidates, which have already entered clinical trials, may be acquired by global pharmaceutical companies for hundreds of millions of dollars.
Investors and OncoArendi have joined forces to deliver to patients more effective and safer drugs than presently available therapies, along with company growth and substantial economic return.
December 23, 2014
Oncoarendi Therapeutics won over 25.5 million zloty
Oncoarendi Therapeutics as the leader of an academic – industrial consortium won over 25.5 million zloty in the second call for proposals of the National Center of Research and Development in the StrategMed program.
The aim of this project is to develop a conceptually novel therapeutic approach in cancer treatment – small molecule immune-modulators to knock-down the ability of tumors to escape immune surveillance.
The project was ranked second among twelve proposals recommended for funding and a total of one hundred and nine evaluated project proposals.
The consortium partners include Medical University of Warsaw, Nencki Institute of Experimental Biology, Institute of Biochemistry and Biophysics, International Institute of Molecular and Cell Biology, commercial partners - Nanovelos Ltd, Scanmed Hospital of St. Rafael, as well as subcontractors - Military Institute of Medicine, Oxford University, Weatherall Institute of Molecular Medicine.
June 2, 2014
On June 2, 2014 OncoArendi received another grant for IP protection
On June 2, 2014 OncoArendi received another grant for IP protection.
January 30, 2014
OncoArendi Therapeutics has signed an exclusive agreement
with one of the top 10 U.S. Universities for the development of inhibitors of new, validated biological targets for the treatment of anti-inflammatory diseases. Further details of this agreement cannot be disclosed at this time.
January 21, 2014
OncoArendi Therapeutics has closed its angel investment round raising
through emission and acquisition of new shares, a total of 3.5 million PLN (approx. 1.1 million USD). Proceeds from this round will be used to supplement public financing in two ongoing discovery programs and launch a third program for the development of anti-inflammatory drug candidates.
November 5, 2013
OncoArendi has signed a contract agreement with the Polish Agency for Enterprise Development
to co-finance international patent protection for the OAT449 group of compounds. The funding sources is Action 5.4.1 of the Innovative Economy Operational Programme and the value of the contract is approximately 0.4M PLN. "Grants fo innovation"
June 6, 2013
The Nencki Institute of Experimental Biology has just signed
a contract with the National Center for Research and Developemnt for co-financing of a 7 Miliion PLN, 30-month collaborative preclinical research and development project of a propriatary oncology drug candidate - OAT449. OncoArendi Therapeutics will be the sole owner of the research results of this joint project and plans to bring the preclinical work through GLP toxicology to the pre-ind stage. The funding source is Action 1.3.1 of the Innovative Economy Operational Programme.
April 9, 2013
A patent application for the OAT-449
drug candidate is simultaneously filed by OncoArendi Therapeutics with the United States Patent and Trademark Office (USPTO) and with the Patent Office of the Republic of Poland.
December 18, 2012
The contract was signed with the National Center for Research and Development
for a three-year program "New drug candidates for targeted therapy of multiple myeloma".
The project will run through September 2015.
September 7, 2012
Funding received for the first discovery program
OncoArendi was successful in securing 1,6M in public financing in an joint application with the Institute of Biophysics and Biochemistry, Polish Academy of Sciences and the International Institute for Molecular and Cell Biology for a project entitled "New drug candidates for targeted therapy of multiple myeloma".